https://www.finanznachrichten.de/nachrichten-2026-01/67407206-johnson-johnson-rybrevant-amivantamab-vmjw-longer-term-results-show-promising-and-durable-responses-in-difficult-to-treat-colorectal-cancer-008.htm
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable...
longer termjohnsonrybrevantamivantamabresults